New folate-modified human serum albumin conjugated to cationic lipid carriers for dual targeting of mitoxantrone against breast cancer.
In the present work, folic acid-modified human serum albumin conjugated to cationic solid lipid nanoparticles were fabricated as a novel carrier for mitoxantrone, a breast cancer therapeutic agent. Dual-targeted drug delivery is a new drug dosing strategy that is frequently used to enhance the therapeutic efficacy of anticancer drugs. Dual targeting of the cancer cells were achieved by dual tagging of human serum albumin and folic acid on the surface of the lipid nanoparticles. The targeted drug loaded nanocomplexes were characterized using transmission electron microscopy along with photon-correlation and fourier-transform infrared spectroscopic techniques. The anti-cancer activity of the nanocomplexes was screened against an in-vitro model of MCF-7 breast cancer cell line to determine the drug efficacy in this novel carrier. The entrapment efficiency and drug loading values for mitoxantrone were calculated to be 97 and 8.84%, respectively. The data from the drug release studies for the system indicated the release profile did not significantly change within a pH range of 5.5-7.4. The hemolysis ratio of the hybrid carrier was less than 5% even at the upper doses of 3 mg/mL, demonstrating its safety for intravenous injection with limited hemolysis and a longer blood circulation time. The cell cytotoxicity results confirmed that the drug hybrid nanocomplex was more toxic to MCF-7 cells compared with the neat drug. Furthermore, the weakly cataionic and small size particles prevented opsonin binding of nanocomplexes, improving blood circulation time and cancer tissue uptake.